Acral melanomas also had more frequent BRAF class 1 mutations (Fig. 5C; 19.7% vs. 6.5%), and amplifications of GAB2 (30.6% vs. 16.1%), TERT (23.8% vs. 12.9%), CARD11 (12.2% vs. 3.2%), and ERBB2 (4.8% vs. 0%), whereas mucosal melanomas had more frequent ATRX (9.7% vs. 2%) and TP53 (9.7% vs. 2.7%) alterations; however, these differences did not exceed significance threshold after correction for multiple testing. This evidence concerns the gene ERBB2 and melanoma.